This could also be applied to engineered T cells that express chimeric antigen receptors (CAR) directed against the tumor, as DGKζ deficiency was also shown to promote CAR T cell-mediated anti-tumor responses (Riese et al., 2013). This evidence concerns the gene DGKZ and neoplasm.